The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2 Biosimilars Make Their Way Toward the European Market

2 Biosimilars Make Their Way Toward the European Market

July 17, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In Europe, two biosimilar treatments, Rixathon and Imraldi, are moving closer to being on the market to treat rheumatic and other diseases.

You Might Also Like
  • Samsung Bioepis Receives Final European Approval for Its Remicade Copy
  • Biosimilars Seek Regulatory Approval in the U.S. & Europe; Plus MTX Underused in the U.S.
  • As Biosimilars Hit, EU Pharma Warns against Blanket Prescribing
Also By This Author
  • FDA to Review Abuse Deterrent Oxycodone Capsule & More

Rituximab Biosimilar Approved
In June, the European Commission approved Rixathon, a biosimilar of rituximab (MabThera), for use in Europe.1 The treatment is approved for all indications of the reference product, including non-Hodgkin’s lymphoma (follicular lymphoma and diffuse large B cell lymphoma), chronic lymphocytic leukemia and immunological diseases, such as rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis. The approval was based on a comprehensive development program, including analytical, preclinical and clinical data, and pharmacokinetic/pharmacodynamic profiles that show Rixathon is similar to rituximab in safety, efficacy and quality.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The approval of biosimilar treatments in Europe is expected to broaden patient access to biologics and enable budget-constrained healthcare systems to reallocate resources to other healthcare priorities.

EMA Recommends Imraldi Approval
Imraldi, a biosimilar of adalimumab (Humira), has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use.2 Its proposed uses include RA, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, pediatric plaque psoriasis, adult and adolescent hidradenitis suppurativa, Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis and uveitis. The European Commission will now review the application and decide whether or not to grant marketing authorization in the EU.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The Marketing Authorization Application for Imraldi was based on data from a randomized, double-blind, 52-week Phase 3 study in patients (n=544) with moderate to severe RA despite treatment with methotrexate. Patients were randomized to receive either Imraldi or Humira. At Week 24, the ACR20 response rates were comparable: 72.4% in the biosimilar-treated group compared with 72.2% in the Humira-treated group. Safety profiles were also comparable.

At Week 24, patients treated initially with Humira (n=254) were re-randomized in a 1:1 ratio either to continue receiving Humira or switch to Imraldi. Patients already on Imraldi (n=254) continued to receive Imraldi. At Week 52, the efficacy, safety and immunogenicity profiles were comparable for all three treatment groups. No treatment-emergent issues or clinically relevant immunogenicity resulted from switching between the products.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Novartis Global. News release: Sandoz receives approval in Europe for rixathon (biosimilar rituximab) to treat blood cancers and immunological diseases. 2017 Jun 19.
  2. Eli Lilly and Company. News release: Japan Ministry of Health, Labor and Welfare (MHLW) grants marketing approval for Olumiant (baricitinib) for the treatment of rheumatoid arthritis. 2017 Jul 3.

 

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, Biosimilars, European Medicines Agency, Psoriasis, rituximab, Rixathon

You Might Also Like:
  • Samsung Bioepis Receives Final European Approval for Its Remicade Copy
  • Biosimilars Seek Regulatory Approval in the U.S. & Europe; Plus MTX Underused in the U.S.
  • As Biosimilars Hit, EU Pharma Warns against Blanket Prescribing
  • Biosimilars Update: FDA Panel Voted to Approve Biosimilars for Etanercept & Adalimumab at July Meeting

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.